首页> 美国卫生研究院文献>Stem Cell Investigation >Cell replacement therapy is the remedial solution for treating Parkinson’s disease
【2h】

Cell replacement therapy is the remedial solution for treating Parkinson’s disease

机译:细胞替代疗法是治疗帕金森氏病的治疗方案

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The selective degeneration of dopaminergic (DA) neurons in Parkinson’s disease (PD) has made an idol target for cell replacement therapies and other emerging surgical treatments. Certainly, by transplantation method, the therapeutic regimens such as human fetal ventral midbrain (hfVM) cells, human embryonic stem cells (hESCs), human neural stem/precursor/ progenitor cells (hNSCs/hNPCs), human mesenchymal stem cells (hMSCs), human induced neural stem cells (hiNSCs), and human induced pluripotent stem cells (hiPSCs) have been used into DA deficient striatum. In recent decades, surgical methods such as deep brain stimulation (DBS) and gene therapies have been used with the aim of treating PD. Though the technology has improved and many treating options arise, the permanent source for curing PD has not been identified yet. In this review, we examine how stem cell therapies have made advancement as a therapeutic source for PD when compared with surgical treatments.
机译:帕金森氏病(PD)中多巴胺能(DA)神经元的选择性变性已成为细胞替代疗法和其他新兴外科治疗的偶像靶标。当然,通过移植方法,治疗方案包括人胎腹中脑(hfVM)细胞,人胚胎干细胞(hESCs),人神经干/前体/祖细胞(hNSCs / hNPC),人间充质干细胞(hMSCs),人类诱导的神经干细胞(hiNSC)和人类诱导的多能干细胞(hiPSC)已用于DA缺陷纹状体。近几十年来,已采用诸如深部脑刺激(DBS)和基因疗法之类的手术方法来治疗PD。尽管技术得到了改进,并且出现了许多治疗选择,但尚未确定用于治疗PD的永久来源。在这篇综述中,我们研究了干细胞疗法与外科疗法相比如何作为PD的治疗来源取得了进步。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号